human T-lymphotropic virus 1 infectious disease

Summary

human T-lymphotropic virus 1 infectious disease (MONDO:0005801) is a disease and 6 clinical trials. Top therapeutic interventions include darifenacin and pentoxifylline. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	human T-lymphotropic virus 1 infectious disease
Mondo ID	MONDO:0005801
EFO	EFO:0007316
MeSH	D015490
UMLS	C0020097
MedGen	6919
GARD	0009645
Is cancer (heuristic)	no

Also known as: HTLV-1 · Human T lymphotropic virus type 1 · Human T-lymphotropic virus 1 caused disease or disorder · Human T-lymphotropic virus 1 disease or disorder · Human T-lymphotropic virus 1 infectious disease · human T-lymphotropic virus 1 infectious disease

Disease family

This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › human T-lymphotropic virus 1 infectious disease

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Subtypes (2): tropical spastic paraparesis, adult T-cell leukemia/lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Raltegravir, Rituximab.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06616675	PHASE4	COMPLETED	Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
NCT01472263	PHASE3	COMPLETED	Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
NCT00076843	PHASE1	COMPLETED	Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
NCT01651819	Not specified	COMPLETED	Urological Physical Therapy in HTLV-1 With Urinary Symptoms
NCT02439918	Not specified	COMPLETED	Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa
NCT02877030	Not specified	COMPLETED	Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DARIFENACIN	4	3
PENTOXIFYLLINE	4	1